Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Research & Development (2020 - 2026)

Maxcyte has reported Research & Development over the past 6 years, most recently at $3.3 million for Q4 2025.

  • Quarterly Research & Development fell 27.72% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.8 million through Dec 2025, down 6.32% year-over-year, with the annual reading at $20.8 million for FY2025, 6.32% down from the prior year.
  • Research & Development was $3.3 million for Q4 2025 at Maxcyte, down from $5.3 million in the prior quarter.
  • Over five years, Research & Development peaked at $6.7 million in Q1 2024 and troughed at $2.7 million in Q3 2021.
  • The 5-year median for Research & Development is $5.5 million (2022), against an average of $5.1 million.
  • Year-over-year, Research & Development tumbled 39.2% in 2021 and then soared 93.86% in 2022.
  • A 5-year view of Research & Development shows it stood at $3.4 million in 2021, then soared by 69.45% to $5.7 million in 2022, then rose by 2.0% to $5.8 million in 2023, then decreased by 21.02% to $4.6 million in 2024, then fell by 27.72% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Research & Development are $3.3 million (Q4 2025), $5.3 million (Q3 2025), and $6.3 million (Q2 2025).